TrialAssure (USA)– a leading, global company focused on developing clinical trial transparency tools – announced that it will partner with Otsuka Pharmaceutical (Japan) to implement its comprehensive transparency management system for all compounds in Otsuka’s drug development pipeline.
TrialAssure’s proprietary clinical trial disclosure management system is a single integrated system designed from the ground up for transparency, to remove redundancy and speed the workflow steps, improve protocol registration compliance, and improve compliance with results disclosures. Compliance is expected to improve by as much as 60 percent in the first year. These efficiencies will be brought to all Otsuka compounds, including central nervous system and neurology, oncology, and cardiovascular and renal system therapeutic areas.
TrialAssure will provide a software-as-a-service (SaaS) solution to Otsuka, allowing their internal disclosure experts the ability to use proven reporting tools, built-in validation, the ability to integrate with their master data system, and the ability to retool core data for application to multiple registries, meeting global reporting requirements for ClinicalTrials.gov, EudraCT, and other global registries.
Established in 1964, Otsuka Pharmaceutical is a leader in the challenging area of mental health and also has research programs on several under-addressed diseases including tuberculosis.